KRAS amplification has been known to be frequently occurred in non-small cell lung cancer (NSCLC) [9, 10], of which the prevalence was reported to approximately 15%, revealing one of the common molecular alterations in NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.